Recombinant IL2RA (Daclizumab Biosimilar) antibody

Catalog No. ABIN5668118

This Human Monoclonal antibody specifically detects IL2RA (Daclizumab Biosimilar) in FACS and BR. It exhibits reactivity toward Human, Cynomolgus and Rhesus Monkey.

Quick Overview for Recombinant IL2RA (Daclizumab Biosimilar) antibody (ABIN5668118)

Target: IL2RA (Daclizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human, Cynomolgus, Rhesus Monkey

Host: Human

Clonality: Monoclonal

Conjugate: This IL2RA (Daclizumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), Blocking Reagent (BR)

Product Details anti-IL2RA (Daclizumab Biosimilar) Antibody

Purpose: Anti-IL-2R [Daclizumab], Human IgG1, kappa

Specificity: Binds to p55 chain of IL2R on human T cells, Tac antigen, which is expressed on T cells activated by mitogens, soluble antigens, and alloantigens but not on resting T cells, thymocytes, B cells, monocytes, activated B cells, leukemic T cell blasts from patients with acute lymphoblastic leukemia, and long-term T cell lines.

Cross-Reactivity: Cynomolgus, Rhesus Monkey

Characteristics:

Original Species of Ab: Human

Original Format of Ab: IgG1

Purification: Protein A affinity purified

Purity: > 98 % as determined by SDS-PAGE

Endotoxin Level: Endotoxin is < 1.0 EU/mg as determined by the LAL method

Immunogen: Cultured T-cells derived from a patient with Mycosis fungoides.

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details for IL2RA (Daclizumab Biosimilar)

Target: IL2RA (Daclizumab Biosimilar)

Target Type: Biosimilar

Background: CD25, Interleukin-2 receptor subunit alpha, IL-2 receptor subunit alpha, IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55

UniProt: P01589